Latest Market Entry News

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

Sprintex has locked in an exclusive Saudi Arabia distribution agreement with Washnah Trading and landed a tender for the King Salman International Airport wastewater project, opening a potential $5 million supply opportunity.

Janus Electric has begun generating export revenue in the US while expanding its electric truck fleet to 28 vehicles and significantly improving its cash position through a $1.4 million R&D tax refund and a $2.75 million finance facility.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Dimerix’s blinded review of its pivotal ACTION3 Phase 3 trial confirms over 90% statistical power to detect DMX-200’s effect on proteinuria, reinforcing the study’s design and regulatory pathway.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.

Streamplay Studio delivers a fourth consecutive quarter of positive cash flow, underpinned by steady publishing revenues and strategic platform growth in new regions.

Echo IQ has taken a major step in its US expansion by deploying its AI-powered EchoSolv AS software at Mount Sinai Health System, one of America’s leading cardiovascular centres. This marks a key milestone in integrating AI into routine cardiology workflows at scale.